Shares of Adaptive Biotechnologies climbed on March 9 after the company announced a reorganization of priorities to spur future growth, including a workforce reduction of approximately 12 percent.
Roche Group member Genentech announced that new data from the pivotal Phase III MURANO and CLL14 studies support the efficacy of fixed-duration, chemotherapy-free Venclexta (venetoclax)-based combinations in certain people with chronic lymphocytic leukemia (CLL) and provide more evidence on the potential value of minimal residual disease.
